Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
0 hedge funds and large institutions have $0 invested in Soleno Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 220 closing their positions.
100% less funds holding
Funds holding: 225 → 0 (-225)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $2.08B → $0 (-$2.08B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 220
120.6% less ownership
Funds ownership: 120.6% → 0% (-121%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$194M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$148M |
| 3 |
BlackRock
New York
|
-$125M |
| 4 |
State Street
Boston,
Massachusetts
|
-$89.8M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$77M |
SLNO Hedge Fund Activity: Q2 2026 in Review
0 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2026, worth a combined $0 — down 100% from $2.08B a quarter earlier.
Sellers outnumbered buyers: 220 funds closed out of SLNO and 0 opened new positions — a net loss of 220 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $194M sold.
- 0 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2026, down from 225 in Q1 2026.
- Funds reported $0 of Soleno Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new Soleno Therapeutics positions in Q2 2026 and 220 closed out, a net change of -220 holders.
- The largest Soleno Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $194M sold.
Based on aggregated 13F filings for Q2 2026.